ReviewDigestive diseases (Basel, Switzerland)2012
Methotrexate: underused and ignored?
Review in Digestive diseases (Basel, Switzerland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Pharmacological Mechanisms of Phytochemicals and Pharmaceutical Agents in Protecting Against Methotrexate-Induced Liver Injury.Oxidative medicine and cellular longevity · 2026Review
- Systemic inhibition ofbioRxiv : the preprint server for biology · 2024Article
- Valsartan Mitigates the Progression of Methotrexate-Induced Acute Kidney Injury in Rats via the Attenuation of Renal Inflammation and Oxidative Stress.Journal of inflammation research · 2024Article
- Advantages of combined photodynamic therapy in the treatment of oncological diseases.Biophysical reviews · 2022Review
- Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough.Clinics in colon and rectal surgery · 2022Review
- miR-770-5p modulates resistance to methotrexate in human colorectal adenocarcinoma cells by downregulating HIPK1.Experimental and therapeutic medicine · 2020Article
- Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases.Inflammatory bowel diseases · 2016Review
- Methotrexate for Inflammatory Bowel Diseases - New Developments.Digestive diseases (Basel, Switzerland) · 2016Review
- Induction of Erythrocyte Membrane Blebbing by Methotrexate-Induced Oxidative Stress.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
For more than a decade, methotrexate has been known to be an effective therapeutic agent in the treatment of steroid-dependent active Crohn's disease. However, international data on medication utilization suggest that this drug is rarely used in clinical practice for an indication of Crohn's disease. This review investigates the potential reasons for the underuse of methotrexate in patients with inflammatory bowel diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.